# Palisade Bio Shares Rise Following Positive Phase 1 Trial Data for Inflammatory Bowel Disease Drug PALI-2108

- URL: https://stocks.freetheai.org/news/palisade-bio-shares-rise-following-positive-phase-1-trial-data-for-inflammatory-cf92e9
- Published: 2026-10-12T12:05:00Z
- Category: company_news; sentiment: bullish; impact: medium
- Symbols: [NASDAQ:PALI](https://stocks.freetheai.org/symbols/NASDAQ-PALI)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Palisade Bio, Inc. (NASDAQ:PALI) presented clinical and pharmacological findings from five poster presentations at the American College of Gastroenterology 2026 Annual Scientific Meeting. The data highlights early clinical activity and target engagement for PALI-2108, an experimental oral therapy under evaluation for ulcerative colitis and Crohn's disease. Following the presentation, company shares rose 6.21% to $1.54.

In a Phase 1a/1b study of five ulcerative colitis patients, treatment with PALI-2108 led to clinical responses in all participants and clinical remission in two, alongside a 62.8% average reduction in modified Mayo scores over seven days. A separate Phase 1b trial in five fibrostenotic Crohn's disease patients showed a 47.5% mean reduction in endoscopic disease scores after 14 days of treatment with mild overall side effects. Two of the presented posters earned ACG Presidential Poster Awards.

The preliminary clinical data and pharmacokinetic analyses support the company's ongoing Phase 2 development programs. Investors and clinicians will watch for further results from the Phase 2 ASCENTRA-UC study, which is testing once-daily 15 mg and 30 mg doses against a placebo in approximately 204 ulcerative colitis patients.

## Key points

- Palisade Bio, Inc. (NASDAQ:PALI) presented findings from five posters on PALI-2108 at the ACG 2026 Annual Scientific Meeting.
- In a 5-patient study for ulcerative colitis, all participants showed clinical response and two achieved clinical remission within seven days.
- A 14-day trial in five Crohn's disease patients demonstrated a 47.5% average reduction in endoscopic disease severity scores.
- Two poster presentations were awarded ACG Presidential Poster Awards at the medical conference.
- The findings support the ongoing Phase 2 ASCENTRA-UC trial, which plans to enroll around 204 ulcerative colitis patients.

## Questions and answers

### What were the trial results for Palisade Bio's PALI-2108 in ulcerative colitis?

In a Phase 1a/1b trial of five patients with ulcerative colitis, all five achieved clinical response and two achieved clinical remission after seven days. Patients experienced a 62.8% average reduction in modified Mayo scores along with decreased markers of tissue inflammation.

### How did Crohn's disease patients respond to PALI-2108 in the study?

A Phase 1b trial of five patients with symptomatic ileal fibrostenotic Crohn's disease showed a 47.5% mean reduction in endoscopic disease scores after 14 days. Two patients achieved endoscopic response and two reached endoscopic remission, with all reported side effects being mild.

### What is the next step for Palisade Bio's PALI-2108 drug program?

Palisade Bio is advancing PALI-2108 in Phase 2 development. This includes the ASCENTRA-UC study, which is evaluating once-daily doses of 15 mg and 30 mg against placebo in approximately 204 patients with ulcerative colitis.